TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call Transcript

And I do think we plan to continue to grow our Briumvi efforts and our team and continue with our R&D platform. But as an overall company, our – I think, our cost structure versus most other companies, not all, but most, is pretty modest, and we’ve kept a pretty lean ship. So I think the consequence of that is we’ll be at profitability probably sooner than most companies would, given the circumstances. In terms of the subcu technical aspects before entering the clinic, I think we’re pretty much over most of the technical hurdles. I think we’ll be able to get into the clinic, I believe, in the next two months or so. And I think there’s a continuing effort to make continued improvements in what we’re working on, which will all just be filtering into the clinical program.

But I don’t think there’s any technical hurdles right now. Just getting – get and going.

Corinne Jenkins: Thank you.

Michael Weiss: Thank you.

Operator: Thank you. We have reached the end of our question-and-answer session. And with that, I would like to turn the floor back over to Mike Weiss for any closing comments.

Michael Weiss: Great. Thank you, everybody. Well, okay, so I just want to thank everyone for joining us today. Hopefully, everyone has been able to see the excitement and enthusiasm that we have here at TG and what’s going on with the company. We were – the first quarter was quite good, in our opinion. We think everything went extremely well. And we look forward to continuing to push forward and achieve even more as we move forward into the remainder of the year. Again, we thank everyone for their support. Most importantly, we want to thank the clinicians and patients who definitely put their trust into TG. The whole team does appreciate it. With that, I’d like to thank everyone for joining us, and have a great day.

Operator: This concludes today’s teleconference. You may disconnect your lines at this time. Thank you for your participation.